Drug companies are quietly pushing through price hikes of 100% — or even more than 1,000% — for a very small but growing number of prescription drugs, helping to drive up costs for insurers, patients and government programs.
Among the examples: Questcor Pharmaceuticals last August raised the wholesale price on Acthar, which treats spasms in babies, from about $1,650 a vial to more than $23,000. Ovation raised the cost of Cosmegen, which treats a type of tumor, from $16.79 to $593.75 in January 2006.
The average wholesale price of 26 brand-name drugs jumped 100% or more in a single cost adjustment last year, up from 15 in 2004, the university study found. In the first half of this year, 17 drugs made the list.
In the article Iowa Women’s Health Study, much of the piece takes many things that are...
The first goal of the Paul Amendment is to reign in FDA overreach in regulating dietary...
To reasonable people it makes a whole lot of sense that the act of pumping tons...
In a medical science first, researchers turned skin cells from heart failure patients into heart muscle...
